title: What is the best antiplatelet agent for prevention of recurrent stroke in Pakistani patients? Do combinations offer significant advantages in the South Asian context?
authors.affiliation: Stroke Service and Vascular Fellowship Program, Aga Khan University Hospital, Stadium Road, Karachi, Pakistan.
authors.forename: Maria
authors.initials: M
authors.lastname: Khan
authors.forename: Ayeesha Kamran
authors.initials: AK
authors.lastname: Kamal
mesh_terms: D044466:Asian People; D001241:Aspirin / Q000627:therapeutic use*; D000077144:Clopidogrel; D004176:Dipyridamole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D010154:Pakistan; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy* / Q000208:ethnology / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin